Please login to the form below

Not currently logged in
Email:
Password:

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

reach the market after Bristol-Myers Squibb’s Opdivo (nivolumab), Merck &Co’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab).

Latest news

More from news
Approximately 118 fully matching, plus 152 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Though its main competitor, BMS’Opdivo, was first to the NSCLC market, Merck’s frontline trial for Keytruda succeeded whereas Opdivo’s failed.

  • Accelerating innovation Accelerating innovation

    Leading this work is an agreement with Bristol-Myers Squibb to study a combination of Cabometyx and that firm’s blockbuster immuno-oncology drug Opdivo (nivolumab) and an agreement with Roche

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II

  • Deal Watch October 2015 Deal Watch October 2015

    Acquisition - company. 2, 300. Five Prime Therapeutics/ Bristol-Myers Squibb. CSF1R antibody programme, incl FPA008 (p1) in immunology/ oncology in combination with Opdivo/ other therapies.

  • Pharma deals in February 2015 Pharma deals in February 2015

    As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Bristol-Myers Squibb's (BMS, $BMY) immunotherapy wonder drug  Opdivo (nivolumab) was poised for lasting success. ... Some chinks in the Opdivo armor were evident back in June 2016, but were largely overlooked.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • Video: Immuno-oncology therapies

    However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.

  • ASCO 2015: What you missed in Chicago

    Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... challenge Opdivo will depend on how the European

  • Blue Latitude Health

    A stumble, but not a fall – what’ s next for Opdivo?. ... Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics